engleski

Value of cerebrospinal fluid visinin-like protein-1 (VILIP-1) for prediction of mild cognitive impairment progression to Alzheimer's disease

Visinin-like protein 1 (VILIP-1) has become very important in past few years as a potential new biomarker of Alzheimer’s disease (AD). This neuronal calcium sensor protein, previously used as a marker of acute ischemic stroke is elevated in cerebrospinal fluid (CSF) of AD patients. The main goal of this study was to test CSF VILIP-1 potential in early AD diagnosis (in patients with mild cognitive impairment ; MCI), differentiation of AD from other primary causes of dementia, and in prediction of cognitive deterioration in AD. VILIP-1 levels were compared with three core (t-tau, Aβ1-42 and p-tau181) and, for the first time, with two additional CSF AD biomarkers (p- tau199 and p-tau231). VILIP-1 successfully differentiated two MCI groups of patients with and without pathological levels of all CSF biomarkers, except for t-tau. VILIP-1/Aβ1-42 and VILIP-1/p-tau231 ratios reached high sensitivities (above 70%) and specificities (above 85%) in differentiating AD patients from healthy controls. Additionally, VILIP-1 differentiated AD from patients with Lewy body disease with 77.1% sensitivity and 100% specificity. Thus, we propose VILIP-1 alone or/and in combination with other CSF biomarkers as a valuable addition to other biomarkers in early diagnosis of AD and in differentiation of AD from LBD. This work was supported by the Croatian Science Foundation grant. no. IP-2014- 09-9730.

VILIP-1 ; Alzheimer’s disease ; cerebrospinal fluid

nije evidentirano